Business Context and Reporting Period
This Form 8-K Current Report was filed by Outlook Therapeutics, Inc. (formerly Oncobiologics, Inc.) on January 22, 2019. The filing addresses a material modification to the rights of security holders regarding the Company's outstanding Series A warrants.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the terms of a warrant amendment.
Material Changes
On January 22, 2019, the Company entered into a third amendment to its Warrant Agreement dated May 18, 2016. The material changes include:
- Expiration Date Extension: The expiration date for the Series A warrants was extended from February 18, 2019, to February 18, 2022.
- Exercise Price Reduction: The exercise price was reduced from $6.60 per share to $1.50 per share.
- Scope: These changes apply to 3,333,333 Series A warrants originally issued in the Company's May 2016 IPO and concurrent private placement.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on financial outlook, or specific risk factors beyond the standard disclosure that the summary is qualified by reference to the full amendment text. A prospectus supplement regarding these changes is to be filed with the SEC and mailed to warrant holders.
Investor Verification Checklist
- Verify the receipt of the prospectus supplement detailing the warrant amendment.
- Confirm the new exercise price of $1.50 per share and the new expiration date of February 18, 2022, for Series A warrants (CUSIP 69012T 115).
- Review Exhibit 10.1 (Amendment #3 to the Warrant Agreement) for complete legal terms.
- Check for any subsequent filings regarding the dilution impact of the reduced exercise price.